A significant proportion of HIV-infected patients admitted to hospital have immunosuppression as a result of failure of highly active antiretroviral therapy

HIV Medicine

Volumn 5, Issue 5, 2004, Pages 360-363

  Manavi, Kaveh ^a   McMillan, A ^a  

^a NHS LOTHIAN   (United Kingdom)

Author keywords

HIV; Hospital admission; Poor immune response despite good viral suppression with HAART

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INTERLEUKIN 2;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE FACILITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SUPERINFECTION; TREATMENT FAILURE; UNITED KINGDOM; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-2; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE; VIRAL LOAD;

EID: 4644278369     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00235.x     Document Type: Article

References (9)

1. Lopez Bernaldo de Quires JC, Miro JM, Pena JM et al. A randomised trial of discontinuation of primary and secondary prophylaxis against Pneumocystis carinii after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001; 344: 159-167.
2. Freedberg KA, Losina E, Weinstein MC et al. The cost-effectiveness of combination anti-retroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-831.
3. Centre for Disease Control. Advancing HIV prevention: new strategies for a changing epidemic - United States 2003. MMWR 2003; 52: 330-332.
4. Grabar S, LeMoing V, Groujard C et al. Clinical outcome of patients with HIV-1 infection according to immunological and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 401-410.
5. Dronda F, Moreno S, Moreno A et al. Long term outcomes among antiretroviral naïve human immunodeficiency infected patients with small increases in CD4 + cell counts after successful virologic suppression. Clin Infect Dis 2002; 35: 1005-1009.
6. Florence E, Lundgren J, Dreezen C et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4: 255-262.
7. Greub G, Ledergerber B, Battegay M et al. Clinical progression survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss cohort study. Lancet 2000; 356: 1800-1805.
8. David D, Nait-Ighil L, Dupont B, Maral J, Gachot B, Theze J. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J Infect Dis 2001; 183: 730-735.
9. Levy Y, Durier C, Krzysiek R et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomised controlled trial. AIDS 2003; 14: 343-351.